TESLA WATCH: Elon Musk Pay Deal In Focus Sarepta stock lost almost a third of its value Tuesday on a "mixed bag" third-quarter report that included two drug failures, delayed test results and a sales beat. Sarepta Therapeutics (SRPT) said late Monday it's planning to ask the Food and Drug Administration to grant a traditional approval to Amondys 45 and Vyondys 53 based on evidence of "positive risk-benefits" in treating Duchenne muscular dystrophy. Both drugs are on the market with accelerated approvals, bu ...